Table of Contents Author Guidelines Submit a Manuscript

Antiphospholipid Syndrome and Antibodies

Call for Papers

Antiphospholipid syndrome is an acquired thrombophilia characterized by venous or artery thrombosis accompanied by or not accompanied by thrombocytopenia in the presence of antiphospholipid antibodies.

Nowadays, several scientists have tried to understand how and why the anti-phospholipid antibodies are linked to thrombotic events and even other nonvascular conditions. The knowledge of these conditions has led to the development of animal models, better knowledge of pathophysiology and new tools for diagnosis, and therapy of antiphospholipid syndrome. In addition, interest on cardiovascular manifestations, livedo reticularis, atherosclerosis, valvulopathy, and neurological and obstetric features is growing in these fields.

We are inviting investigators to submit their scientific papers, including original reviews, focused on aspects related to antiphospholipid syndrome and antibodies in humans or also in animal models. Potential topics include, but are not limited to:

  • Recent developments in pathophysiology of antiphospholipid syndrome/antibodies
  • Experimental studies on antiphospholipid syndrome/antibodies
  • Clinical vascular manifestations of antiphospholipid syndrome
  • Obstetric features in antiphospholipid syndrome
  • Treatment of vascular manifestations of antiphospholipid syndrome
  • Obstetric treatment of antiphospholipid syndrome
  • Cardiovascular manifestations of antiphospholipid syndrome
  • Atherosclerosis and antiphospholipid syndrome/antibodies
  • Neurological features and antiphospholipid syndrome/antibodies

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Manuscript DueFriday, 28 March 2014
First Round of ReviewsFriday, 20 June 2014
Publication DateFriday, 15 August 2014

Lead Guest Editor

Guest Editors

  • Roger Levy, Faculdade de Ciências Medicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
  • Yehuda Shoenfeld, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel